n-3多不饱和脂肪酸对2型糖尿病大鼠肝脏脂质沉积的影响

鲁敏 文秀英 许明旺 黄文凡 刘丽芳 许诣

中国药学杂志 ›› 2010, Vol. 45 ›› Issue (7) : 510-515.

PDF(1397 KB)
PDF(1397 KB)
中国药学杂志 ›› 2010, Vol. 45 ›› Issue (7) : 510-515.
论著

n-3多不饱和脂肪酸对2型糖尿病大鼠肝脏脂质沉积的影响

  • 鲁敏a,文秀英b*,许明旺b,黄文凡a,刘丽芳a,许诣a
作者信息 +

Influence of n-3 Polyunsaturated Fatty Acids on Liver Lipidomics in Type 2 Diabetic Rats

  • LU Mina,WEN Xiu-yingb*,XU Ming-wang b,HUANG Wen-fana,LIU Li-fanga,XU Yia
Author information +
文章历史 +

摘要

目的 观察n-3多不饱和脂肪酸(n-3-PUFAs)对2型糖尿病大鼠糖脂代谢和肝脏脂质沉积的影响,并探讨其可能的分子机制。方法 用高脂高糖饲料喂养加链脲佐菌素(STZ)腹腔注射方法建立的2型糖尿病模型。将成模大鼠随机分为模型组8只、n-3-PUFAs组和格列喹酮组各10只,另设正常对照组10只,持续灌胃12周。比较用药前、用药6周和12周末各组大鼠体重、血清空腹血糖(FBG)、甘油三酯(TG)、总胆固醇(TC)水平。断头处死大鼠后,比较各组大鼠腹腔内脂肪指数、肝脏指数、肝脏脂肪变程度和肝组织TG、TC含量;并用RT-PCR法检测肝组织固醇调节元件结合蛋白-1c(SREBP-1c)、脂肪酸合成酶(FAS)和乙酰辅酶A羧化酶(ACC)mRNA的表达;Western印迹法检测肝组织SREBP-1蛋白的表达。结果 n-3-PUFAs组大鼠腹腔脂肪指数和体重均较模型组明显增加(P<0.01),血清TG降低(P<0.01),肝脏TG含量、肝指数及肝脏脂肪变程度记分升高(P<0.01),肝组织SREBP-1c、FAS和ACC mRNA表达升高(P<0.01),肝组织SREBP-1蛋白表达升高(P<0.01)。结论 n-3-PUFAs能降低血清TG,但会导致腹腔脂肪增加及肝脏脂质沉积,与n-3-PUFAs不能抑制2型糖尿病状态下SREBP-1c及其下游脂肪合成相关酶FAS及ACC的表达有关。

Abstract

OBJECTIVE To study the influence of n-3 polyunsaturated fatty acids (n-3-PUFAs) on liver lipidomics in type 2 diabetic rats, and to investigate the possible molecular mechanism. METHODS Type 2 diabetes rats were induced by high-fat and high-sugar diet followed with streptozotocin injection. All rats were randomly divided into four groups:the control group, the model group, the n-3-PUFAs group and gliquidone(Glurenor) group. The animals were sacrificed after the 12 weeks of administration. The fasting blood glucose, the weight of liver, the index of liver, TG and TC contents in liver and serum were measured. The level of SREBP-1 in liver was measured by Western blot. SREBP-1 mRNA, FAS mRNA and ACC mRNA expressions were measured with RT-PCR. RESULTS The rats in n-3-PUFAs group showed characters of obesity. The TG in serum of the n-3-PUFAs group was lower than that in the model group (P<0.01). The TG contents in liver, the weight of liver and the index of liver were higher than those of model group(P<0.01). The expression levels of SREBP-1c, FAS and ACC mRNA in the n-3-PUFAs group were higher than those in the model group(P<0.01). CONCLUSION Although n-3-PUFAs reduces the level of serum TG, it causes obesity and liver lipidomics, and it can′t suppress the overexpression of SREBP-1c, FAS and ACC in the liver of type 2 diabetic rats.

关键词

n-3多不饱和脂肪酸 / 2型糖尿病 / 脂质沉积 / 固醇调节元件结合蛋白-1c

Key words

n-3 polyunsaturated fatty acids / type 2 diabetic / lipid deposit / sterol regulatory element-binding protein 1c

引用本文

导出引用
鲁敏 文秀英 许明旺 黄文凡 刘丽芳 许诣. n-3多不饱和脂肪酸对2型糖尿病大鼠肝脏脂质沉积的影响[J]. 中国药学杂志, 2010, 45(7): 510-515
LU Min;WEN Xiu-ying;XU Ming-wng;HUNG Wen-fn;LIU Li-fng;XU Yi. Influence of n-3 Polyunsaturated Fatty Acids on Liver Lipidomics in Type 2 Diabetic Rats[J]. Chinese Pharmaceutical Journal, 2010, 45(7): 510-515

参考文献


[1] MCPHERSON R, GAUTHIER A. Molecular regulation of SREBP function:the Insig-SCAP connection and isoform-specific modulation of lipid synthesis[J]. Biochem Cell Biol,2004, 82 (1):201-211.
[2] FORETZ M, GUICHARD P, FERRE P, et al. SREBP-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes[J]. Proc Natl Acad Sci USA, 1999, 96(22):12737-12742.
[3] EDWARDS P A, TABOR D, KAST H R, et al. Regulation of gene expression by SREBP and SCAP[J]. Biochim Biophys Acta,2000, 1529(1-3):103-113.
[4] GUO X H,LIU Z H,LI H, et al. Type 2 diabetes mellitus induced by diets and its features of renal involvement in rat[J]. Chin J Diabet(中国糖尿病杂志),2002,10(5):290-294.
[5] DANDA R S, HABIBA N M, RINCON C H, et al. Kidney involvement in a nongenetic rat model of type 2 diabetes[J]. Kidney Int,2005,68(6):2562-2571.
[6] CHINESE SOCIETY OF HEPATOLOGY OF NONALCOHOLIC AND ALCOHOLIC FATTY LIVER GROUP. Diagnostic standard of nonalcoholic fatty liver[J]. Chin J Hepatol(中华肝脏病杂志), 2001, 9(6):325.
[7] CLORE J N, STILLMAN J S, JING L, et al. Differential effect of saturated and polyunsaturated fatty acids on hepatic glucose metabolismin humans[J]. Am J Physiol Endocrinol Metab, 2004, 287(2):358-365.
[8] FLACHS P, ROSSMEISL M, BRYHN M, et al. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism[J].Clin Sci (Lond), 2009, 116(1):1-16.
[9] SEKIYA M, YAHAGI N, MATSUZAKA T, et al.Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression[J]. Hepatology,2003, 38(6):1529-1539.
[10] CAPANNI M, CALELLA F, BINGINI M R, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease:a Pilot study[J]. Aliment Pharmacol Ther, 2006, 23(8):1143-1151.
[11] PEYRON C E, TAVERNA M, MICHELE G M, et al. Dietary (n-3) polyunsaturated fattyacids up-regulate plasma leptin in insulin-resistant rats[J]. J Nutr,2002, 132(8):2235-2240.
[12] CHEN Y J,ZHOU G H,XU X L. Disease preventing and curing function of n-3 polyunsaturated fatty acids[J]. China Oils Fats(中国油脂),2006,31(9):31-34.
[13] MONTELL E, TURINI M, MAROTTA M, et al. DAG Accumulation from saturated fatty acidsdesensitizes insulin stimulation of glucose uptake in muscle cells[J]. Am J Physiol Endocrinol Metab, 2001, 280(2):229-237.
[14] HAN P,LU Y,XIA F, et al. Effect of polyunsaturated fatty acids on hepatic triglyceride content and insulin resistance[J]. Chin J Diabet(中国糖尿病杂志), 2007,15(7):405-407.
[15] IRVING G F, FREUND L Y, ERIKSDOTTER J M. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer′s disease:the Omega-3 Alzheimer′s disease study[J]. J Am Geriatr Soc,2009, 57(1):11-17.
[16] SONG X Y, CHEN Q, QI X Y. Effect of Liuwei Dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients[J]. Chin J Integr Med(中国中西医结合杂志), 2004,24(12):1087-1090.
[17] NITIYANANT W, SRIUSSADAPORN S, DEEROCHANAWONG C, et al. The efficacy and safety of gliquidone in Thai diabetics[J]. J Med Assoc Thai,1997, 80(12):771-777.
[18] LIU G L, ZHAO X J, DU J, et al. Clinical observation on the efficacy of glurenorm in the treatment of type 2 diabetes[J]. Liaoning J Pract Diabetol,2004, 12(3):58-60.
PDF(1397 KB)

Accesses

Citation

Detail

段落导航
相关文章

/